FINWIRES · TerminalLIVE
FINWIRES

$CGON

7 stories mentioning CGON

Every FINWIRES story that references CGON, newest first.

Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.7%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Cigna (CI) shares fell 1.6% after Barclays downgraded the stock to equalweight from overweight, and lowered its price target to $304 from $310.Brazil on Tuesday cleared pharmaceutical company EMS to sell the country's first generic version of Novo Nordisk's (NVO) Ozempic shot, Bloomberg reported. EMS plans to sell the generic version, called Ozivy, for 30% less than Ozempic, and it expects it to hit the market within 30 days, the report said. Novo shares were down 1.5%.Eli Lilly (LLY) said it has struck deals to buy three vaccine developers in all-cash deals with a combined value of up to $3.83 billion to build its infectious disease portfolio. Lilly shares rose 0.5%.CG Oncology (CGON) shares fell 3.8% after the firm said that Ambaw Bellete, its president and chief operating officer, will exit the company, effective June 30.

$CGON$CI$LLY$NVO
Sectors

Sector Update: Healthcare Stocks Decline Tuesday Afternoon

Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.5%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Brazil on Tuesday cleared pharmaceutical company EMS to sell the country's first generic version of Novo Nordisk's (NVO) Ozempic shot, Bloomberg reported. EMS plans to sell the generic version, called Ozivy, for 30% less than Ozempic, and it expects it to hit the market within 30 days, the report said. Novo shares were down 1.4%.Eli Lilly (LLY) said it has struck deals to buy three vaccine developers in all-cash deals with a combined value of up to $3.83 billion to build its infectious disease portfolio. Shares rose 1.3%.CG Oncology (CGON) shares declined 2.9% after the firm said that Ambaw Bellete, its president and chief operating officer, will exit the company, effective June 30.BioRestorative Therapies (BRTX) shares jumped 18% after the firm said it has completed dosing in its phase 2 trial assessing BRTX-100 to treat chronic lumbar disc disease.

$BRTX$CGON$LLY$NVO
Wire

CG Oncology Chief Operating Officer Ambaw Bellete to Depart

CG Oncology (CGON) said in a Tuesday regulatory filing that its president and chief operating officer Ambaw Bellete will exit the company, effective June 30.The company also appointed Arthur Kuan as president, according to the filing.Price: $61.07, Change: $-3.19, Percent Change: -4.96%

$CGON
Wire

CG Oncology's Creto Combination Could Drive Better Efficacy in BCG-Exposed NMIBC, UBS Says

CG Oncology's (CGON) initial data from its phase 2 study support a potential cretostimogene and Gemcitabine combination strategy to drive better efficacy in Bacillus Calmette-Guerin-exposed non-muscle invasive bladder cancer, UBS said in a Monday note.The firm said that the cretostimogene and Gemcitabine combination showed a clean safety profile with no high-grade treatment-related adverse events, further supporting their combinability.UBS noted, however, that long-term durability of the combination remains to be seen.The firm said that the Bacillus Calmette-Guerin-exposed population is an underappreciated opportunity, and continued de-risking efficacy data could drive long-term upside.UBS has a buy rating on the stock and a $90 price target.Price: $65.36, Change: $-1.58, Percent Change: -2.35%

$CGON
Wire

CG Oncology's BLA Completion Target for Creto in Q4 to Comfort Investors, RBC Says

CG Oncology's (CGON) target to complete a biologics license application for cretostimogene monotherapy, or creto, in Q4 will provide investors with comfort, RBC Capital Markets said in a Friday note.Cretostimogene monotherapy is currently being evaluated as a treatment for high-risk non-muscle invasive bladder cancer, according to the note.The firm said that while the application completion target is later than hoped, the added clarity puts an end date on the submission, assuaging manufacturing concerns.RBC said that considering favorable regulatory designations, the therapy could receive approval toward H2 of 2027.RBC said that a readout for the PIVOT-006 trial is on track for H1 of 2026, with the drug expected to meet its endpoints and drive an about 15% jump in stock movement as a base case.The firm has an outperform speculative risk rating on the stock and increased its price target to $81 from $79.Price: $69.82, Change: $+0.20, Percent Change: +0.29%

$CGON
Wire

CG Oncology Pivot-006 Data in Early June Seen as 'Complex' Catalyst, RBC Says

CG Oncology's (CGON) Pivot-006 study, currently evaluating Cretostimogene Grenadenorepvec in intermediate-risk non-muscle invasive bladder cancer, is a "complex" catalyst, RBC Capital Markets said in a Monday note.The firm said complexity stems from limited historical data to anchor readout expectations, combined with a recent run-up in shares and a more challenging tactical setup ahead of the catalyst.RBC expects data from the trial in early June and models Cretostimogene delivering a nearly 40% risk reduction, which it estimates would drive about 20% upside in the stock. The firm also highlights a greater than $1.2 billion US opportunity in intermediate-risk disease, adding to the drug's established profile in high-risk non-muscle invasive bladder cancer.Other key catalysts include additional clinical readouts across its bladder cancer program and a potential BLA filing in H2, RBC said.The firm has an outperform, speculative risk rating on the stock and raised its price target to $79 from $73.Price: $68.66, Change: $-0.02, Percent Change: -0.03%

$CGON
Insider Trading

CG Oncology Insider Sold Shares Worth $1,138,956, According to a Recent SEC Filing

James Mulay, Director, on April 17, 2026, sold 15,600 shares in CG Oncology (CGON) for $1,138,956.SEC Filing:https://www.sec.gov/Archives/edgar/data/1991792/000119312526164013/xslF345X05/ownership.xml

$CGON